These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 11805241)

  • 41. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
    Kornhuber ME; Zierz S
    Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
    [No Abstract]   [Full Text] [Related]  

  • 42. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1835-46. PubMed ID: 24993135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Diagnosis and treatment of multiple sclerosis. Update, 2003].
    Jarius S; Hohlfeld R; Voltz R
    MMW Fortschr Med; 2003 May; 145 Suppl 2():88-91, 93, 95. PubMed ID: 14579493
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.
    Goodkin DE
    West J Med; 1994 Sep; 161(3):292-8. PubMed ID: 7975569
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Editorial: the pitfalls of combination therapy.
    Vermersch P
    Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
    [No Abstract]   [Full Text] [Related]  

  • 48. Multiple sclerosis. Treatment is shifting.
    Mayo Clin Health Lett; 2003 Jan; 21(1):6. PubMed ID: 12619619
    [No Abstract]   [Full Text] [Related]  

  • 49. Concomitant therapy for multiple sclerosis.
    Stuart WH; Vermersch P
    Neurology; 2004 Dec; 63(11 Suppl 5):S28-34. PubMed ID: 15596733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Considerations in the treatment of relapsing-remitting multiple sclerosis.
    Calabresi PA
    Neurology; 2002 Apr; 58(8 Suppl 4):S10-22. PubMed ID: 11971122
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A practical guide to pediatric multiple sclerosis.
    Huppke P; Gärtner J
    Neuropediatrics; 2010 Aug; 41(4):157-62. PubMed ID: 21086219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical markers of therapeutic response to disease modifying drugs.
    Pozzilli C; Prosperini L
    Neurol Sci; 2008 Sep; 29 Suppl 2():S211-3. PubMed ID: 18690494
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies--an update.
    Donoghue S; Greenlees C
    Expert Opin Investig Drugs; 2000 Jan; 9(1):167-71. PubMed ID: 11060669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
    Chofflon M
    BioDrugs; 2005; 19(5):299-308. PubMed ID: 16207071
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
    Dhib-Jalbut S
    Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapies in neurologic disorders.
    Graves D; Vernino S
    Med Clin North Am; 2012 May; 96(3):497-523, x. PubMed ID: 22703853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of magnetic resonance imaging studies in multiple sclerosis.
    Cerreta E
    J Neurosci Nurs; 1998 Oct; 30(5):290-301. PubMed ID: 9816560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

  • 60. Primary progressive multiple sclerosis.
    Montalban X; Rio J
    Neurol Sci; 2001 Nov; 22 Suppl 2():S41-8. PubMed ID: 11794476
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.